The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction

Volume: 26, Issue: 6, Pages: 593 - 600
Published: Sep 6, 2021
Abstract
Over the past decade, soluble guanylate cyclase (sGC) activators and stimulators have been developed and studied to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The sGC enzyme plays an important role in the nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway, that has been largely untargeted by current guideline directed medical therapy (GDMT) for HFrEF. Disruption of the NO-sCG-cGMP...
Paper Details
Title
The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction
Published Date
Sep 6, 2021
Volume
26
Issue
6
Pages
593 - 600
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.